AIM ImmunoTech (AIM) Return on Equity (2018 - 2024)
Historic Return on Equity for ImmunoTech (AIM) over the last 8 years, with Q3 2024 value amounting to 3.11%.
- ImmunoTech's Return on Equity fell 26700.0% to 3.11% in Q3 2024 from the same period last year, while for Sep 2024 it was 3.11%, marking a year-over-year decrease of 26700.0%. This contributed to the annual value of 4.57% for FY2024, which is N/A changed from last year.
- According to the latest figures from Q3 2024, ImmunoTech's Return on Equity is 3.11%, which was down 26700.0% from 4.06% recorded in Q2 2024.
- In the past 5 years, ImmunoTech's Return on Equity ranged from a high of 0.15% in Q1 2020 and a low of 4.06% during Q2 2024
- Over the past 3 years, ImmunoTech's median Return on Equity value was 0.89% (recorded in 2023), while the average stood at 1.55%.
- Per our database at Business Quant, ImmunoTech's Return on Equity crashed by -4900bps in 2020 and then tumbled by -26700bps in 2024.
- Quarter analysis of 3 years shows ImmunoTech's Return on Equity stood at 0.2% in 2020, then plummeted by -590bps to 1.35% in 2023, then tumbled by -130bps to 3.11% in 2024.
- Its Return on Equity was 3.11% in Q3 2024, compared to 4.06% in Q2 2024 and 2.94% in Q1 2024.